SynOV 1.3
Alternative Names: SynOV-1.3Latest Information Update: 03 Feb 2021
At a glance
- Originator Beijing SyngenTech
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 13 Jan 2021 Preclinical trials in Liver cancer in China (Parenteral) (Beijing SyngenTech pipeline, January 2021)